Sigma Planning Corp Trims Position in Lam Research Co. (NASDAQ:LRCX)

Sigma Planning Corp decreased its holdings in Lam Research Co. (NASDAQ:LRCX) by 66.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 638 shares of the semiconductor company’s stock after selling 1,276 shares during the quarter. Sigma Planning Corp’s holdings in Lam Research were worth $499,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Orion Capital Management LLC bought a new stake in Lam Research during the 3rd quarter valued at approximately $25,000. BluePath Capital Management LLC purchased a new position in shares of Lam Research in the 3rd quarter valued at approximately $28,000. OFI Invest Asset Management bought a new stake in shares of Lam Research during the third quarter valued at approximately $30,000. Asset Dedication LLC grew its stake in Lam Research by 56.7% in the third quarter. Asset Dedication LLC now owns 47 shares of the semiconductor company’s stock worth $30,000 after purchasing an additional 17 shares during the period. Finally, Valued Wealth Advisors LLC bought a new position in Lam Research in the fourth quarter worth $30,000. Hedge funds and other institutional investors own 84.61% of the company’s stock.

Insider Transactions at Lam Research

In related news, CAO Christina Corrreia sold 647 shares of the business’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $972.03, for a total transaction of $628,903.41. Following the completion of the sale, the chief accounting officer now directly owns 5,541 shares in the company, valued at $5,386,018.23. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Lam Research news, Director Abhijit Y. Talwalkar sold 882 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $972.03, for a total value of $857,330.46. Following the completion of the transaction, the director now directly owns 10,541 shares in the company, valued at $10,246,168.23. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CAO Christina Corrreia sold 647 shares of the company’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $972.03, for a total transaction of $628,903.41. Following the completion of the transaction, the chief accounting officer now directly owns 5,541 shares of the company’s stock, valued at approximately $5,386,018.23. The disclosure for this sale can be found here. Insiders have sold 7,029 shares of company stock worth $6,559,489 in the last quarter. Company insiders own 0.32% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently commented on LRCX. Mizuho boosted their target price on shares of Lam Research from $935.00 to $960.00 and gave the company a “buy” rating in a report on Thursday. Stifel Nicolaus boosted their price objective on shares of Lam Research from $950.00 to $1,050.00 and gave the stock a “buy” rating in a research note on Tuesday, April 16th. Cantor Fitzgerald restated a “neutral” rating and issued a $1,100.00 price objective on shares of Lam Research in a report on Thursday. Susquehanna lowered their target price on shares of Lam Research from $880.00 to $850.00 and set a “neutral” rating for the company in a report on Thursday. Finally, Deutsche Bank Aktiengesellschaft began coverage on Lam Research in a research note on Thursday, April 11th. They issued a “hold” rating and a $1,000.00 price target on the stock. Seven analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat, Lam Research has a consensus rating of “Moderate Buy” and an average price target of $950.85.

Lam Research Trading Up 1.9 %

Lam Research stock opened at $901.47 on Friday. Lam Research Co. has a one year low of $493.42 and a one year high of $1,007.39. The business’s fifty day moving average is $943.68 and its 200 day moving average is $807.04. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.06 and a quick ratio of 2.02. The stock has a market capitalization of $118.18 billion, a PE ratio of 33.15, a price-to-earnings-growth ratio of 3.20 and a beta of 1.51.

Lam Research (NASDAQ:LRCX) last posted its earnings results on Wednesday, April 24th. The semiconductor company reported $7.79 EPS for the quarter, topping analysts’ consensus estimates of $7.26 by $0.53. The business had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.72 billion. Lam Research had a net margin of 25.35% and a return on equity of 45.76%. The firm’s revenue was down 2.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $6.99 EPS. On average, sell-side analysts predict that Lam Research Co. will post 28.96 EPS for the current year.

Lam Research Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, April 3rd. Stockholders of record on Wednesday, March 13th were given a dividend of $2.00 per share. This represents a $8.00 annualized dividend and a dividend yield of 0.89%. The ex-dividend date of this dividend was Tuesday, March 12th. Lam Research’s payout ratio is currently 29.42%.

Lam Research Company Profile

Lam Research Corporation designs, manufactures, markets, refurbishes, and services semiconductor processing equipment used in the fabrication of integrated circuits. The company offers ALTUS systems to deposit conformal films for tungsten metallization applications; SABRE electrochemical deposition products for copper interconnect transition that offers copper damascene manufacturing; SOLA ultraviolet thermal processing products for film treatments; and VECTOR plasma-enhanced CVD ALD products.